摘要 |
The present invention provides the use of somatostatin antagonists for treating and preventing HISS-dependent insulin resistance and hemorrhage induced insulin resistance. The present further provides pharmaceutical compositions comprising a somatostatin antagonist and a pharmaceutically acceptable liver targeting compound.
|